Manoela Dantas

Manoela Dantas

Auto-generated profile, based on publicly available information

Manoela Dantas

Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases Institute, Cleveland Clinic Foundation, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Open access
PDF file
VAVictor F. A. Almeida
Victor F. A. Almeida
GDGlaudir Donato
Glaudir Donato
MDManoela Dantas
Manoela Dantas
EDEliana F. R. Duraes
Eliana F. R. Duraes
Background: Ketorolac, a nonsteroidal anti-inflammatory drug, is a promising opioid-sparing option for postoperative pain control. However, its impact on platelet function raises concerns about bleeding risk. Reduction mammaplasty carries a known risk of hematoma, and this study aimed to assess whether perioperative ketorolac increases this risk. Methods: We searched Cochrane Central, Embase, PubMed, and Web of Science databases for studies involving breast reduction patients who did or did not receive perioperative ketorolac. The primary outcome was hematoma formation, with secondary outcomes distinguishing between cases requiring surgery and those managed conservatively. A random-effects model calculated pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was assessed using the I 2 statistic. Results: Seven studies involving 3,418 patients were included—1991 in the ketorolac group and 1427 in the control group. The hematoma incidence was 6.13% in the ketorolac group versus 6.73% in controls. Meta-analysis revealed a significantly increased risk of hematoma in ketorolac users (OR 2.63, 95% CI 1.58–4.37, p < 0.001, I 2 = 37.5%), particularly in cases managed conservatively (OR 2.72, 95% CI 1.37–5.38, p = 0.004, I 2 = 26.3%). Sensitivity analysis reinforced these findings, also demonstrating an association between ketorolac and hematomas requiring reoperation. Conclusion: Perioperative ketorolac is associated with an increased risk of hematoma following breast reduction surgery. While it provides effective opioid-sparing analgesia, its use should be carefully considered, especially in patients with higher bleeding risks. Further randomized trials are needed to refine safety recommendations. Level of Evidence II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266

3 October 2025 in Microsurgery
Verified
Journal Article
Open access
VAVictor F. A. Almeida
Victor F. A. Almeida
GDGlaudir Donato
Glaudir Donato
ACAndressa Alves de Carvalho
Andressa Alves de Carvalho
WCWanessa Alves de Carvalho
Wanessa Alves de Carvalho
ALAmmar Lakda
Ammar Lakda
EDEliana F. R. Duraes
Eliana F. R. Duraes
Background: Autologous breast reconstruction using abdominally based flaps is common post‐mastectomy, but donor‐site pain often leads to prolonged opioid use. The transversus abdominis plane ( TAP ) block is a common regional anesthesia technique, with bupivacaine as the standard anesthetic. Liposomal bupivacaine ( LB ), a prolonged‐release formulation, aims to extend pain relief and reduce opioid consumption, though its efficacy remains debated. Objective: This systematic review and meta‐analysis compared LB versus plain bupivacaine ( PB ) in TAP blocks for autologous breast reconstruction, focusing on opioid consumption, pain scores, and hospital stay. Methods: A systematic search identified randomized controlled trials and observational studies comparing LB (with or without PB ) to PB in TAP blocks. Data were pooled using a random‐effects model ( I 2 ≥ 25%) or fixed‐effects model ( I 2 < 25%). Results: Six studies (429 patients) met inclusion criteria. LB was associated with significant reduction in opioid consumption on postoperative days ( POD ) 1 ( MD = −4.99 mg; 95% CI : [−8.42; −1.56], p < 0.01, I 2 = 0%) and POD 2 ( MD = −3.35 mg; 95% CI : [−5.74; −0.96], p < 0.01, I 2 = 0%). Pain scores were significantly lower on POD 2 and POD 3. No difference in hospital stay was found ( MD = −0.17; 95% CI : [−0.52; 0.18], p = 0.34, I 2 = 83.1%). Conclusion: LB reduced opioid consumption during the first 48 h postoperatively and modestly improved pain control on POD 2 and POD 3, but did not shorten hospital stay. Further large‐scale RCTs are needed to validate its benefits.

29 December 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
VAVictor F. A. Almeida
Victor F. A. Almeida
GDGlaudir Donato
Glaudir Donato
MDManoela Dantas
Manoela Dantas
EDEliana F. R. Duraes
Eliana F. R. Duraes

27 April 2026 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
VAVictor F. A. Almeida
Victor F. A. Almeida
MDManoela Dantas
Manoela Dantas
GDGlaudir Donato
Glaudir Donato
AAAvneep Aggarwal
Avneep Aggarwal